Drug Profile
Research programme: diabetes mellitus therapeutics - ImmuPharma
Alternative Names: Gastric inhibitory peptide - ImmuPharma; GIP - ImmuPharma; GLP1 - ImmuPharma; Glucagon-like peptide 1 - ImmuPharmaLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator ImmuPharma
- Developer CNRS; ImmuPharma; University of Bordeaux
- Class Peptide hormones; Recombinant proteins
- Mechanism of Action Gastric inhibitory polypeptide stimulants; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Diabetes-mellitus in France
- 28 Jul 2018 No recent reports of development identified for research development in Diabetes-mellitus in United Kingdom
- 27 Jun 2014 Early research in Diabetes mellitus in France (unspecified route)